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ABSTRACT 
Background: Progressive multifocal leukoencephalopathy is a serious condition linked to 
certain diseases and immunosuppressant therapies, including the α4 integrin antagonist 
natalizumab. No cases have been reported to date with vedolizumab, a selective 
antagonist of the α4β7 integrin expressed on gut-homing lymphocytes. This analysis aimed 
to describe the current and future expected occurrence of progressive multifocal 
leukoencephalopathy with vedolizumab use, were the risk the same as in other 
populations in which this disease has been studied.  
Methods: The expected number of vedolizumab-associated progressive multifocal 
leukoencephalopathy cases was estimated up to May 19, 2016 and modelled up to 2034. 
These estimates were based on the cumulative exposure to the drug, assuming an 
equivalent risk to that of patients treated with natalizumab or those from other reference 
populations where progressive multifocal leukoencephalopathy has been examined. 
Future cases were modelled based on similar risks and projected sales. 
Results: The cumulative vedolizumab exposure was estimated at 54,619 patient-years, 
with a 95% confidence interval of 0.0–6.75 cases per 100,000 patient-years. An estimated 
30.2 (95% confidence interval 19.4–40.9) cases of progressive multifocal 
leukoencephalopathy would have occurred if vedolizumab had the same risk as that of 
natalizumab. There would be a 50% chance of the first case occurring by 2018, assuming 
an equivalent risk to the general population. 
Conclusions: These analyses indicate the risk of progressive multifocal 
leukoencephalopathy with vedolizumab is small, and unlikely to be above 6.75 cases per 
100,000 patient-years. 
 
Key words: Epidemiology, clinical trials, progressive multifocal leukoencephalopathy, 
inflammatory bowel disease, vedolizumab  
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INTRODUCTION 
Progressive multifocal leukoencephalopathy (PML) is a disabling and potentially fatal 
neurological syndrome caused by the John Cunningham virus (JCV) that can occur in the 
setting of severe immunosuppression.1, 2 In addition to infection with human 
immunodeficiency virus (HIV), the use of immunomodulatory therapies – including the α4 
integrin antagonist natalizumab – has been associated with the development of PML.3-5 
Although PML in patients treated with natalizumab is a relatively rare event, the risk 
increases with duration of use of >2 years, prior use of immunosuppressants, and JCV 
seropositivity.3, 6 Currently available data suggest that natalizumab-associated PML is 
associated with a better survival rate compared with PML in other populations, such as in 
patients with HIV infection (prior to the availability of highly active antiretroviral therapy) 
and in transplant recipients.7-9 Nonetheless, the natalizumab-associated PML mortality rate 
is approximately 24%, and surviving patients are frequently left with disability.8, 10 
 
Vedolizumab (Entyvio®; Takeda Pharmaceuticals, Deerfield, IL, USA) is licensed to treat 
adults with moderately to severely active ulcerative colitis (UC) or Crohn’s disease (CD) 
who have had an inadequate response with, lost response to, or were intolerant to a tumor 
necrosis factor (TNF) antagonist or immunomodulator, or had an inadequate response 
with, were intolerant to, or demonstrated dependence on corticosteroids.11  
 
As a humanized monoclonal antibody that antagonizes α4β7 integrin,11 vedolizumab has 
some similarity in its mechanism of action to that of natalizumab. Natalizumab is a 
humanized IgG4 monoclonal antibody that inhibits the α4-subunit of the α4β1 integrin, 
preventing it from binding to vascular cell adhesion molecule 1 (VCAM-1).11-13 This results 
in decreased immune surveillance within the central nervous system (CNS) and thus 
increasing the risk of PML development.4, 14 However, vedolizumab does not inhibit binding 
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at VCAM-1,15 and instead selectively targets the α4β7 integrin expressed on gut-homing 
lymphocytes, with non-gut homing T lymphocytes remaining unaffected.16, 17 
 
At the time this paper was submitted for publication, there have been no cases of PML 
reported in association with vedolizumab use.  This, combined with the gastrointestinal 
selective mechanism of action of vedolizumab, supports the hypothesis that this agent 
does not predispose to the development of PML.18-20 However, given the rarity of the 
condition, the knowledge that the PML risk increases with duration of natalizumab use of 
>2 years, and the fact that vedolizumab is a relatively novel therapy (United States [US] 
and European approval was obtained in 2014), we cannot yet have absolute confidence in 
this supposition.1, 6, 11, 13 Monitoring for new or worsening neurologic signs or symptoms is 
therefore recommended with vedolizumab treatment, and continued monitoring has been 
ongoing since clinical development.11, 13  
 
Greater certainty regarding the risk of PML with vedolizumab treatment would be of great 
benefit to patients and clinicians. Hence, our aim here is to use the totality of available 
randomized controlled trial (RCT) and observational data to explore how confident we can 
be that vedolizumab does not predispose to the development of PML.   
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MATERIALS AND METHODS 
 
Patients and Data Collection 
The estimated vedolizumab cumulative exposure to May 19, 2016 was calculated based 
on data from both the clinical trial program (see Table, Supplemental Digital Content 1, 
which lists the clinical studies included in the risk modelling analyses) and post-marketing 
sales (a total of >8 years in the clinical trial program and up to 2 years’ post-marketing 
exposure). For clinical trial data, exposure was calculated as the sum of individual 
exposure periods for each clinical trial patient. For post-marketing data, it was assumed 
that each patient was treated with vedolizumab 300 mg (1 vial) every 8 weeks. Exposure 
was calculated based on sales, and to estimate duration of use we assumed a steady 
attrition rate between 10–30% per year (based on 7-year long-term observational study 
data) up to the data cut-off point. 
  
Data on adverse events (AEs) up to May 19, 2016 were obtained from the Takeda Global 
Safety Database, which contains vedolizumab data from clinical trials and post-marketing 
reporting, held in accordance with routine pharmacovigilance practices. Vedolizumab AE 
data were obtained from spontaneous reports submitted to Takeda directly from 
consumers, manufacturers, healthcare professionals, and regulatory authorities; from 
Takeda monitoring of the scientific and medical literature; and from solicited reports from 
clinical trials as well as patient support and market research programs.  
 
From these data (patient-years [PY] of exposure and number of cases of PML), we 
estimated the risk of PML as cases per 100,000 patient years of exposure; 95% 
confidence intervals (CIs) around this were calculated assuming a Poisson distribution (the 
probability of observing at least k events was also based on the assumption that events 
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follow a Poisson distribution). The risk estimates were adjusted to account for the 
increased risk of PML after 2 years of therapy. 
 
Ethical Considerations 
Patients enrolled in clinical trials, post-authorization safety studies, patient support, and 
market research programs provided informed consent for participation in the studies, 
including the collection of AE data. Institutional Review Board review and approvals were 
obtained for these studies.  
 
Expected Number of Vedolizumab-Associated PML Cases Relative to 
Natalizumab 
The total number of expected cases of vedolizumab-associated PML was estimated 
assuming vedolizumab use conferred a risk equivalent to that associated with natalizumab 
use. Previously published rates of PML in natalizumab users were utilized, as described in 
the US prescribing information and published data (0.56/1000 to 13/1000 over 6 years’ 
exposure).5, 21 
 
Patients were grouped according to level of exposure to vedolizumab and risk factors 
(prior immunosuppressant use [same risk assumed for all immunosuppressants including 
azathioprine, methotrexate, and TNF antagonists] and anti-JCV antibody-positive status) to 
mirror patient stratification described in the natalizumab US prescribing information. To do 
this we estimated the levels of prior immunosuppressant use and anti-JCV antibody-
positive status. Based on vedolizumab clinical trial data, it was assumed that 
approximately 80% of patients had prior immunosuppressive use.22 Because JCV antibody 
testing was not required by the vedolizumab clinical trial protocols, an estimate was made 
based on published rates (anti-JCV antibody-positivity was assumed in approximately 50% 
of patients).23, 24 Vedolizumab patient counts in each stratum were multiplied by the 
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corresponding risk estimate for natalizumab and summed to obtain the total number of 
expected cases; the 95% CI estimate (calculated using the StatXact 9 software) was 
based on the normal approximation to the Poisson distribution.25 
 
Expected Number of Vedolizumab-Associated PML Cases Relative to Other 
Populations 
The expected occurrence of PML in patients receiving vedolizumab was also calculated, 
assuming the same PML incidence rate (per 100,000 PY) as in the general population and 
in populations in which the risk of PML is known to be elevated. These groups include 
patients with rheumatoid arthritis (RA), HIV-free systemic lupus erythematosus (SLE) 
patients, HIV-free non-Hodgkin’s lymphoma (NHL) patients, HIV-free autoimmune 
vasculitis patients, HIV-free chronic lymphocytic leukemia patients, bone marrow 
transplant recipients, patients with HIV, heart and/or lung transplant recipients, and HIV-
free rituximab-exposed NHL patients.9, 26-30 The expected number of PML cases and 
associated 95% CIs for vedolizumab, if the risk were equivalent to each reference 
population, were calculated by multiplying the population incidence rate (per 100,000 PY) 
and 95% CI by the total PY of exposure to vedolizumab. Because data for these 
populations were not reported in strata of immunosuppression use or JCV positivity, it was 
not possible to standardize these estimates. 
 
Estimated Probability of Future Vedolizumab-Associated PML Cases  
The probability of a future PML case in vedolizumab-treated patients was estimated, 
assuming the same risk as in three reference populations: the general population, patients 
with RA, and patients with SLE (without HIV).26, 27 The current total number of PYs of 
vedolizumab exposure was estimated as specified above (in the ‘Patients and Data 
Collection’ section), and the likely future exposure to vedolizumab from 2016 to 2034 was 
estimated based on sales projections. The probabilities of a case arising for each year 
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were estimated using the Poisson approximation to the binomial distribution (frequentist 
approach), using the expected cumulative PY by that year as the number of trials, and the 
PML probability in the reference population as the event probability. The probabilities of ≥2 
and ≥3 future PML cases in vedolizumab-treated patients were similarly estimated. A 
sensitivity analysis using a Bayesian approach was also conducted for the general 
population-based analysis. A conjugate beta distribution was assumed for the prior 
distribution of the PML probability, with the following two shape parameters: α = 1 + 
number of PML events in current trials (i.e. zero), and β = the current total PY + the 
reciprocal of the estimated PML probability of the general population.31 The predictive 
probability of ≥1 PML future occurrence for each year was estimated by a beta-binomial 
distribution based on number of trials equal to the forecasted cumulative PY by that year.   
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RESULTS 
Up to May 19, 2016, the cumulative vedolizumab exposure was approximately 54,619 PY, 
which comprised 7641 PY (3821 patients) from clinical trials, and an estimated 46,978 PY 
from post-marketing use (Table 1). To date, no cases of PML have been observed in 
patients treated with vedolizumab. The CI calculated around the rate of 0 cases of PML 
per 100,000 PY of exposure was 0–6.75 cases of PML per 100,000 PY of exposure.  
 
Expected Number of Vedolizumab-Associated PML Cases  
Based on cumulative exposure to vedolizumab, 30.2 cases of PML (95% CI 19.4–40.9) 
would be expected if vedolizumab exposure conferred the same risk as that of 
natalizumab (Table 2). Similarly, given cumulative vedolizumab exposure of approximately 
54,619 PY, assuming an equivalent risk to the different reference populations, the number 
of expected PML cases for vedolizumab-treated patients is lowest in the general 
population (0.2; 95% CI 0.05–0.3) and patients with RA (0.6; 95% CI 0.2–1.4). Higher 
numbers would be expected in other disease populations, including bone marrow 
transplant recipients (19.3; 95% CI 0.5–107.8) and heart and/or lung transplant recipients 
(67.7; 95% CI 13.7–197.2), with the highest number anticipated in HIV-free rituximab-
exposed NHL patients (131.1; 95% CI 54.6–305.9) (Table 3). 
 
Estimated Probability of Future Vedolizumab-Associated PML Cases  
If the risk of developing PML with vedolizumab were the same as in the general 
population, the estimated probability of observing the first PML case in vedolizumab-
treated patients would be approximately 50% by 2018, and 90% by 2022 (Figure 1A). An 
estimated ≥2 or ≥3 cases will occur by 2021 (Figure 1B) and 2023 (Figure 1C), 
respectively, with a >50% probability.  
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Assuming the risk of PML with vedolizumab were identical to that in patients with RA or 
HIV-free SLE, the first PML case would be likely to occur earlier than predicted for the 
general population (>90% probability of first case by 2019 and 2017, respectively; Figure 
1A). Assuming the risk is the same as in RA, ≥2 or ≥3 cases would occur with a >90% 
probability by 2020 and 2021, respectively, and ≥2 or ≥3 cases would occur with a >90% 
probability by 2018 and 2019, respectively, assuming an identical risk to that in patients 
with HIV-free SLE (Figures 1B and 1C).  
 
In the sensitivity analysis, using the Bayesian approach and historical data of the general 
population as prior information, we estimate that the probability of observing the first PML 
case in vedolizumab users will occur with 50% probability during 2019, over a year later 
than in the estimate based on the frequentist approach (Supplemental Digital Content 2).  
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DISCUSSION  
In this analysis, we provide evidence supporting the hypothesized lower risk of PML in 
users of vedolizumab versus those of natalizumab. We also estimate the numbers of PML 
cases that might be expected if vedolizumab users had risk levels equivalent to those of a 
variety of other population groups. Of these, the risk of PML in the general population or in 
patients with RA, HIV-free SLE, HIV-free NHL, or autoimmune vasculitis would be 
consistent with the observed absence of PML cases to date. The current data are, 
however, not consistent with vedolizumab carrying the elevated risk of PML seen in HIV 
infection, heart/lung transplantation, or rituximab use. Because there have been no cases 
of PML observed to date, it is difficult to precisely estimate the true level of risk, although 
our current analysis suggests it is not likely to be above 6.75 cases per 100,000 PY. 
Assuming an identical risk to that in the general population, the first PML case with 
vedolizumab treatment was estimated to occur with a 50% probability in 2019 and 2018, 
using Bayesian and frequentist approaches, respectively. 
 
The analysis we present here has methodological challenges. Because we do not have 
access to the health records of the vast majority of patients receiving vedolizumab, we 
have not reviewed individual patients' medical records to confirm an absence of PML. 
However, we have gone to great lengths to attempt to ascertain cases through analysis of 
available RCT and observational data. Bearing in mind the serious nature of PML, it would 
be expected that all cases occurring in patients receiving vedolizumab in routine clinical 
practice would be reported. Additionally, direct information regarding prior 
immunosuppressant use or the presence of JCV in those receiving vedolizumab outside 
clinical trials is not available. However, there is no reason to believe that those receiving 
vedolizumab in the post-marketing setting would be less likely to have used 
immunosuppressants than those in the RCTs. Rather we think it  unlikely that many 
prescribers will yet be using a ‘top-down’ approach starting initial therapy with 
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vedolizumab, or be using it as rescue therapy in acute flares. Immunosuppressant use 
might well therefore be almost universal in vedolizumab users, in which case the 
assumption we have made will be highly conservative (we will have underestimated the 
likely level of PML if risks were equivalent to those in natalizumab). 
 
A further set of challenges with this analysis relates to the available data on population 
levels of PML. Ideally, we would standardize for age, sex, and immunosuppressant use for 
all populations; however, the rarity of the condition means that the population data required 
to achieve this is unavailable. Our estimates, with the exception of that relating to 
natalizumab, therefore do not take into account any of these confounding factors.  
 
When considering the limitations of this analysis, however, it is important to consider the 
alternatives. It could be argued that absolute proof that there is no risk could be 
demonstrated only through a randomized, placebo-controlled clinical trial, with PML 
development as the primary outcome measure and with sufficient power to demonstrate 
equivalence between vedolizumab-treated patients and those receiving placebo. Such a 
trial would arguably be unethical and would require an unfeasibly large patient population 
(for example, in the context of zero events and based on the statistical ‘rule of three’, a 
sample size of 300,000 PY [for each of the vedolizumab and placebo cohorts] would be 
required to rule out a risk of >1 event per 100,000 PY with 95% confidence). Therefore, 
targeted observational research such as the current analysis is likely to be the best 
available option in this scenario. Due to uncertainty in the current estimate of the true risk 
of PML associated with vedolizumab, we have provided estimates of the probability of 
observing future PML cases under various risk scenarios.  
 
Despite the limitations of the available data, it is nonetheless useful to consider the 
conclusions that can confidently be made. To begin with, it is clear that if the risk of PML 
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were the same as with natalizumab, 30 cases of PML would have been observed by May 
19, 2016 in patients treated with vedolizumab, with a 95% CI lower bound of 19 cases. 
Therefore, we can reasonably conclude that there is a much lower risk of PML with 
vedolizumab than with natalizumab. Such a conclusion is not surprising because 
natalizumab is a humanized IgG4 monoclonal antibody that inhibits the α4 subunit of the 
α4β1 integrin, preventing it from binding to VCAM-1. By preventing α4β1 binding to VCAM-1 
on endothelial cells, extravasation of immune inflammatory cells into the brain is 
prevented,4, 14 leading to decreased immune surveillance in the CNS that is hypothesized 
to predispose to development of PML with natalizumab use.4, 14 By contrast, vedolizumab 
is the first available agent that selectively targets the α4β7 integrin heterodimer, specifically 
preventing extravasation of immune inflammatory cells into the gut, with no evidence of an 
impact on immune surveillance in the CNS.15-17 We can also conclude that, if the PML risk 
does not increase with long-term vedolizumab use, it is unlikely that the true level of risk is 
above 6.75 cases per 100,000 PY given current exposure estimates.  
 
To put this into context, such a risk should be compared not only to the known risk of PML 
associated with other treatments (as has been done here), but also with the uncertainty 
regarding other medications such as corticosteroids and thioguanines, which have both 
been associated with the development of this condition. A 2009 study of nationwide US 
inpatient sample data showed that 20% of cases of PML in rheumatic diseases were 
associated with the use of only very mild immunosuppression with an antimalarial or low-
dose prednisolone,32 and analysis of French pharmacovigilance reports shows that PML 
has significantly elevated reported odds ratios (in excess of 4) for both prednisolone and 
azathioprine.33 Finally, we should consider what other risks patients might run with 
alternative therapies. In many cases the alternatives to vedolizumab will be either 
immunosuppression or surgery. Neither of these is risk-free, with a colectomy being 
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associated with mortality of about 1%34 and azathioprine with a cumulative lymphoma risk 
of approximately 0.4–4.0% over 10 years (depending on age).35 
 
In conclusion, our calculations have shown that the risk of PML with vedolizumab is likely 
to be significantly lower than that with natalizumab. With no cases having been reported to 
date, the eventual level of risk cannot be precisely estimated; however, these analyses 
indicate the risk is small, and unlikely to be above 6.75 cases per 100,000 PY. 
Confirmation as to whether the risk is appreciably greater than in the background 
population remains to be seen as further data is accrued from continued post-marketing 
surveillance.   
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TABLES 
TABLE 1. Estimated exposure to vedolizumab (up to May 19, 2016; data cut-off). 
Vedolizumab 
exposure, 
months 
Post-
marketing: 
~46,978 
PYa 
Clinical 
trials: 
~7641 
PYb 
Total: 
~54,619 
PY 
1–24 46,978 2442 49,420 
25–48 0 517 517 
49–72 0 862 862 
Total 
patients 
46,978 3821 50,799 
aThe number of PY of exposure to vedolizumab in the post-marketing setting is an approximation 
based on shipping data; it is assumed that each patient received vedolizumab 300 mg (1 vial) every 
8 weeks. 
bThe estimated number of PY of vedolizumab exposure in patients who have received at least one 
dose of vedolizumab in completed and ongoing clinical trials up to May 19, 2016. 
PY, patient-years.  
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TABLE 2. Estimated cumulative incidence of PML with vedolizumab in anti-JCV antibody-
positive patientsa up to May 19 2016b, assuming a risk equivalent to that associated with 
natalizumab use (stratified by risk factor). 
Vedolizumab 
exposure, 
months 
No prior 
immunosuppressant 
use, expected cases 
Prior 
immunosuppressant 
use, expected 
casesc 
1–24 2.77 19.77 
25–48 0.16 2.48 
49–72 0.52 4.48 
Total 
expected 
cases of PML 
(95% CI) 
30.17 (19.41–40.94) 
aBased on previous reports, it was assumed that 50% of patients with Crohn’s disease were anti-JCV 
antibody-positive.24 
bExpected cases based on an estimated 54,619 patient-years of vedolizumab exposure in completed 
and ongoing clinical trials (n = 3821) and post-marketing (n = 46,978) up to May 19, 2016; for post-
marketing data it is assumed that each patient received vedolizumab 300 mg (1 vial) every 8 weeks 
(see Table 1). 
cBased on vedolizumab clinical trial data, it was assumed that 80% of patients had prior 
immunosuppressant use.22 
CI, confidence interval; JCV, John Cunningham virus; PML, progressive multifocal 
leukoencephalopathy. 
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TABLE 3. Expected cases of PML with vedolizumab given current cumulative exposure if the 
risk were equivalent to that of selected reference populations. 
Reference population (country) 
Population 
incidence rate for 
PML (per 100,000 
PY [95% CI]) 
Expected PML 
cases (95% CI)a 
General population (Sweden)27  0.3 (0.1–0.6) 0.2 (0.05–0.3) 
RA (Sweden)27 1.0 (0.3–2.5) 0.6 (0.2–1.4)  
HIV-free SLE (USA)26  2.4 (0.1–13.2) 1.3 (0.05–7.2)  
HIV-free NHL (USA)26 8.3 (1.7–24.2) 4.5 (0.9–13.2) 
HIV-free autoimmune vasculitis (USA)26 10.8 (0.3–60.4) 5.9 (0.2–33.0) 
HIV-free chronic lymphocytic leukemia 
(USA)26 
11.1 (0.3–61.7) 6.1 (0.2–33.7) 
Bone marrow transplant recipients (USA)26  35.4 (0.9–197.3) 19.3 (0.5–107.8) 
Patients with HIV (Switzerland)b,29  60 (40–100) 32.8 (21.9–54.6) 
Heart and/or lung transplant recipients (USA, 
The Netherlands)9 
124 (25–361) 67.7 (13.7–197.2) 
Patients with HIV (Denmark)c,28  130 (80–190) 71.0 (43.7–103.8) 
HIV-free rituximab-exposed NHL (Italy)30 240 (100–560) 131.1 (54.6–305.9) 
aBased on cumulative exposure of approximately 54,619 PY using May 19, 2016 estimates from 
clinical trials (7641 PY) and post-marketing data (46,978 PY). 
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bStudy performed before and after the introduction of combination antiretroviral therapy in 1996. 
cIncidence rate covers period between 2000 and 2006 (late highly active antiretroviral therapy era). 
CI, confidence interval; HIV, human immunodeficiency virus; NHL, non-Hodgkin’s lymphoma; PML, 
progressive multifocal leukoencephalopathy; PY, patient-years; RA, rheumatoid arthritis; SLE, 
systemic lupus erythematosus. 
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FIGURE LEGENDS 
FIGURE 1. Estimated probability of observing (A) ≥1 PML case, (B) ≥2 PML cases, and 
(C) ≥3 PML cases with vedolizumab over time, assuming equivalent risk to reference 
populations. 
HIV, human immunodeficiency virus; PML, progressive multifocal leukoencephalopathy; PY, 
patient-years; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus. 
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Supplemental Digital Content 1. Table that lists the clinical studies included in the risk 
modelling analyses.doc 
 
Supplemental Digital Content 2. Figure illustrating the outcomes of the sensitivity analysis for 
estimation of the probability of observing ≥1 PML case with vedolizumab over time, assuming 
equivalent risk to the general population (frequentist vs Bayesian approach). 
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SUPPLEMENTARY TABLE 1. Clinical studies included in the risk modelling analyses. 
 
Study number Title References 
C13001  A phase 1, single ascending dose, randomized, placebo-controlled, double-blind study to determine 
the safety, tolerability, pharmacokinetics, and pharmacodynamics of MLN0002 in healthy subjects 
Wyant T et al. Cytometry Part B 2016;90:168 
C13002  A phase 2, randomized, placebo-controlled, double-blind study to determine the safety, tolerability, 
pharmacokinetics, and pharmacodynamics of MLN0002 following multiple intravenous doses in 
patients with ulcerative colitis 
https://clinicaltrials.gov/ct2/show/NCT01177228 
(accessed August 22, 2017); 
Rosario M et al. Aliment Pharmacol Ther 2015;42:188 
Wyant T et al. Cytometry Part B 2016;90:168 
C13004 A phase 2, multiple dose, open-label study to determine the long-term safety of MLN0002 in patients 
with ulcerative colitis and Crohn's disease 
https://clinicaltrials.gov/ct2/show/NCT00619489 
(accessed August 22, 2017) 
 
C13005 A phase 1, single dose, open-label study to determine the pharmacokinetics, safety, and tolerability of 
MLN0002 in healthy subjects across a range of low and high body weights 
https://www.takedaclinicaltrials.com/files2/C13005-RDS-
2008-10-14.pdf (accessed August 22, 2017) 
C13006 A phase 3, randomized. placebo-controlled, blinded, multicenter study of the induction and 
maintenance of clinical response and remission by MLN0002 in patients with moderate to severe 
ulcerative colitis 
https://clinicaltrials.gov/ct2/show/NCT00783718 
(accessed August 22, 2017); 
Feagan BG et al. N Engl J Med 2013;369:699 
C13007 A phase 3, randomized, placebo-controlled, blinded, multicenter study of the induction and 
maintenance of clinical response and remission by MLN0002 in patients with moderate to severe 
Crohn's disease 
https://clinicaltrials.gov/ct2/show/NCT00783692 
(accessed August 22, 2017); 
Sandborn WJ et al. N Engl J Med 2013;369:711 
C13008 A phase 3, open-label study to determine the long-term safety and efficacy of vedolizumab in subjects 
with ulcerative colitis and Crohn's disease 
https://www.clinicaltrialsregister.eu/ctr-
search/search?query=eudract_number:2008-002784-14 
(ongoing) (accessed August 22, 2017) 
C13009 A phase 1 single dose study to determine the pharmacokinetics, pharmacodynamics, safety, and 
tolerability of a lyophilized formulation (Process C drug product) of MLN0002 in healthy subjects 
Wyant T et al. Cytometry Part B 2016;90:168 
C13010 A phase 1 study of the bioavailability of MLN0002 administered by subcutaneous and intramuscular 
injection to healthy male subjects 
https://www.takedaclinicaltrials.com/files2/C13010-RDS-
2010-04-08.pdf (accessed August 22, 2017) 
C13011 A phase 3, randomized, placebo-controlled, blinded, multicenter study of the induction of clinical 
response and remission by vedolizumab in patients with moderate to severe Crohn’s disease 
https://clinicaltrials.gov/ct2/show/NCT01224171 
(accessed August 22, 2017); 
Sands BE et al. Gastroenterology 2014;147:618 
C13012 A phase 1 single-arm study to evaluate the effects of a single intravenous dose of vedolizumab 
(MLN0002) on the CD4+:CD8+ lymphocyte ratio in the cerebrospinal fluid of healthy subjects 
https://www.takedaclinicaltrials.com/files2/C13012-RDS-
2011-12-12.pdf (accessed August 22, 2017) 
C13013 A phase 1, randomized, double-blinded, placebo-controlled single dose study in healthy subjects to 
determine the immune response to systemic and gut antigenic challenge in the presence of 
vedolizumab  
https://clinicaltrials.gov/ct2/show/NCT01981616 
(accessed August 22, 2017); 
Wyant T et al. Gut 2015;64:77 
MLN0002_401 Entyvio (vedolizumab) long-term safety study: an international observational prospective cohort study 
comparing vedolizumab to other biologic agents in patients with ulcerative colitis or Crohn's disease 
https://clinicaltrials.gov/ct2/show/NCT02674308 
(accessed August 22, 2017) 
 
MLN0002-3026 A randomized, double-blind, double-dummy, multicenter, active-controlled study to evaluate the 
efficacy and safety of vedolizumab iv compared to adalimumab SC in subjects with ulcerative colitis 
https://www.clinicaltrialsregister.eu/ctr-
search/search?query=eudract_number:2015-000939-33 
(accessed August 22, 2017) 
MLN0002-3027 A phase 3 randomized, double-blind, placebo-controlled study, with a vedolizumab iv reference arm, 
to evaluate the efficacy and safety of vedolizumab subcutaneous as maintenance therapy in subjects 
with moderately to severely active ulcerative colitis who achieved clinical response following open-
label vedolizumab intravenous therapy 
https://www.clinicaltrialsregister.eu/ctr-
search/search?query=eudract_number:2015-000480-14 
(accessed August 22, 2017)  
  
Supplementary Material For Review
  
MLN0002-3031 A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of 
vedolizumab subcutaneous as maintenance therapy in subjects with moderately to severely active 
Crohn’s disease who achieved clinical response following open-label vedolizumab intravenous 
therapy 
https://www.clinicaltrialsregister.eu/ctr-
search/search?query=eudract_number:2015-000481-58 
(accessed August 22, 2017) 
 
Frequentist approach
Bayesian approach
Year
P
r
o
b
a
b
i
l
i
t
y
 
o
f
 
o
b
s
e
r
v
i
n
g
 
≥
1
 
P
M
L
 
(
%
)
2016 2017 2018 2019 2020 2021 2022 2023 2024 2026 20282027 20302029 20322031 20342033
0
10
20
30
40
50
60
70
80
90
100
2025
Supplementary Material For Review
 1 
 
  Dr Fatima Bhayat, MBChB, MPH, 
PhD, MFPM 
Takeda Development Centre 
Europe Ltd 
61 Aldwych 
London, WC2B 4AE 
Bret Lashner, M.D. and Fabio 
Cominelli , M.D., Ph.D. 
Editors in Chief 
Inflammatory Bowel Diseases 
  
 
September 28, 2017 
 
Dear Dr Lashner and Dr Cominelli 
 
Re: IBD-D-17-00765 What is the risk of progressive multifocal leukoencephalopathy in patients with 
ulcerative colitis or Crohn's disease treated with vedolizumab? 
 
Thank you for confirming your tentative acceptance of our manuscript “What is the risk of progressive 
multifocal leukoencephalopathy in patients with ulcerative colitis or Crohn's disease treated with vedolizumab?” 
for publication in Inflammatory Bowel Diseases.  
 
On behalf of my coauthors, I would like to thank the reviewers for their thoughtful and positive feedback. As 
requested by Reviewer 1, we have reassigned Figure 2 as a Supplementary figure mentioned on pages 11 and 
the legend on page 22 of the revised manuscript draft. We hereby submit this revised version for your final 
consideration as we understand that no further revisions are required at this stage. 
 
We look forward to working with you to bring our research to the public domain. 
 
Kind regards 
 
 
 
Dr Fatima Bhayat, MBChB, MPH, PhD, MFPM 
Executive Medical Director - GI TA Lead 
Global Patient Safety 
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